Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 10/20 | 0.38 |
| ▸ | DRD2 | P14416 | 2/20 | 0.38 |
| ▸ | DRD3 | P35462 | 2/20 | 0.38 |
| ▸ | DRD4 | P21917 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.34 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.33 |
| ▸ | PPOX | P50336 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7105482 | 1.00 | ADRB3 (0.38) | ADRB3DRD2DRD3DRD4BACE1 | |
| SCHEMBL176915 | 1.00 | ADRB3 (0.38) | ADRB3DRD2DRD3DRD4BACE1 | |
| SCHEMBL7981042 | 0.86 | ADRB3 (0.38) | ADRB3BACE1TRPV1PTGS1PTGS2 | |
| SCHEMBL7981040 | 0.86 | ADRB3 (0.38) | ADRB3BACE1TRPV1PTGS1PTGS2 | |
| SCHEMBL7105760 | 0.86 | ADRB3 (0.38) | ADRB3TRPV1 | |
| SCHEMBL177028 | 0.86 | ADRB3 (0.38) | ADRB3TRPV1 | |
| SCHEMBL2243705 | 0.86 | ADRB3 (0.38) | ADRB3TRPV1 | |
| SCHEMBL5195520 | 0.79 | KIF11 (0.41) | ADRB3DRD2DRD3DRD4PTGS1 | |
| SCHEMBL5195514 | 0.79 | KIF11 (0.41) | ADRB3DRD2DRD3DRD4PTGS1 | |
| SCHEMBL7977260 | 0.79 | GSTO1 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8304443-B2 | Indazole derivatives | ASAHI KASEI PHARMA CORPORATION (JP) | 2012-11-06 | — | — | US | disclosed |
| US-8008506-B2 | Indazole compounds | ASAHI KASEI PHARMA CORPORATION (JP) | 2011-08-30 | — | — | US | disclosed |
| US-20100160256-A1 | INDAZOLE COMPOUNDS | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-06-24 | — | — | US | disclosed |
| US-20100152265-A1 | INDAZOLE DERIVATIVES | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-06-17 | — | — | US | disclosed |
| EP-1277736-B1 | NOVEL BICYCLIC COMPOUNDS | ASAHI KASEI PHARMA CORP (JP) | 2007-08-08 | — | — | EP | disclosed |
| US-7049445-B2 | Bicyclic compounds | ASAHI KASEI PHARMA CORPORATION (JP) | 2006-05-23 | — | — | US | disclosed |
| US-6861444-B2 | Bicyclic compounds | ASAHI KASEI PHARMA CORPORATION (JP) | 2005-03-01 | — | — | US | disclosed |
| US-20040127546-A1 | for treating or preventing diabetes, obesity, hyperlipidemia, digestive diseases, depression or urinary disturbances; beta 3-agonist | ASAHI KASEI PHARMA CORPORATION (JP) | 2004-07-01 | — | — | US | disclosed |
| US-20030191174-A1 | Eating disorders; antidiabetic agents; gastrointestinal disorders | ASAHI KASEI PHARMA CORPORATION (JP) | 2003-10-09 | — | — | US | disclosed |
| EP-0882707-B1 | NOVEL TRICYCLIC COMPOUNDS AND DRUG COMPOSITIONS CONTAINING THE SAME | ASAHI CHEMICAL IND (JP) | 2003-10-08 | — | — | EP | disclosed |
| US-20030139475-A1 | Novel tricyclic compounds and drug compositions containing same | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 2003-07-24 | — | — | US | disclosed |
| US-6545053-B1 | Aminoethoxyfluorene derivatives are beta-3 adrenaline receptor agonists and are useful as drugs for the treatment and prevention of diabetes, obesity, hyperlipemia, etc. | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 2003-04-08 | — | — | US | disclosed |
| EP-1277736-A1 | NOVEL BICYCLIC COMPOUNDS | Asahi Kasei Kabushiki Kaisha (JP) | 2003-01-22 | — | — | EP | disclosed |
| US-6187809-B1 | BETA-3 ADRENALINE RECEPTOR AGONIST DRUGS FOR THE TREATMENT OF DIABETES, OBESITY, AND HYPERLIPEMIA; 2-(N-(2-(DIBENZOFURAN-3-YLOXY)ETHYL)AMINO)-1-PHENYLETHANOL, FOR EXAMPLE | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 2001-02-13 | — | — | US | disclosed |
| US-6172099-B1 | CARBAZOLE, DIBENZOFURAN, OR DIBENZOTHIOPHENE DERIVATIVES; DIETETICS, ANTIDIABETIC AGENTS; ANTILIPEMICS | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 2001-01-09 | — | — | US | disclosed |
| EP-0997458-A1 | NOVEL TRICYCLIC COMPOUNDS HAVING SATURATED RINGS AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 2000-05-03 | — | — | EP | disclosed |
| US-6037362-A | CARBAZOLE DERIVATIVES; DEPROTECTING, AMINATION; ANTILIPEMIC AND ANTIDIABETIC AGENTS; B-ADRENALINE RECEPTOR AGONISTS; DIETETICS | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 2000-03-14 | — | — | US | disclosed |
| EP-0882707-A1 | NOVEL TRICYCLIC COMPOUNDS AND DRUG COMPOSITIONS CONTAINING THE SAME | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1998-12-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030139475-A1 | Novel tricyclic compounds and drug compositions containing same | ADRB3, MC2R, NR3C1 | ADRB3 1/4885DRD2 212/4885DRD3 108/4885 |
| US-20040127546-A1 | for treating or preventing diabetes, obesity, hyperlipidemia, digestive diseases, depression or urinary disturbances; beta 3-agonist | GPR119, ADRB3, DBH | ADRB3 2/4885DRD2 263/4885DRD3 103/4885 |
| US-20030191174-A1 | Eating disorders; antidiabetic agents; gastrointestinal disorders | GPR119, GIPR, SLC5A2 | ADRB3 953/4885DRD2 182/4885DRD3 87/4885 |
| US-20100152265-A1 | INDAZOLE DERIVATIVES | ADRB3, INSR, ADRB1 | ADRB3 1/4885DRD2 849/4885DRD3 208/4885 |
| US-20100160256-A1 | INDAZOLE COMPOUNDS | GPR119, ADRB1, ADRA1A | ADRB3 5/4885DRD2 781/4885DRD3 391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.